Who is at risk
- Smoking — roughly doubles risk, and quitting lowers it over time.
- Obesity and high blood pressure, both independently.
- Chronic kidney disease, particularly with long-term dialysis.
- Family history, and inherited syndromes — von Hippel-Lindau, hereditary papillary RCC, Birt-Hogg-Dubé, hereditary leiomyomatosis. These often cause kidney cancer younger and in both kidneys.
- Occupational exposures such as trichloroethylene.
- Age and sex — most common after 55 and about twice as common in men.
Finding it early
There is no screening test for the general population, and the classic triad taught in textbooks — blood in the urine, flank pain and a palpable mass — is now rare and signals advanced disease when it appears.
In practice, most kidney cancers today are found incidentally: a CT or ultrasound done for abdominal pain, injury or an unrelated problem shows a mass. This is the main reason the proportion caught early has risen.
Symptoms worth acting on: visible blood in the urine (always), persistent flank or back pain on one side, a lump in the side or abdomen, unexplained weight loss, persistent fever without infection, or unexplained anemia.
If kidney cancer runs in your family — especially at a young age or in both kidneys — ask about genetic counselling. People with a known syndrome are surveilled with regular imaging, which is screening in the sense that matters.
How it’s diagnosed
Kidney cancer is unusual: it is often diagnosed and treated without a biopsy first. Cross-sectional imaging (CT or MRI with contrast) is accurate enough that a mass with characteristic features is frequently taken to surgery on imaging alone.
Biopsy is used when the diagnosis is uncertain, when treatment would be ablation or surveillance rather than surgery, or when the disease is advanced and the subtype will determine drug therapy.
Subtype matters: clear cell is the most common and behaves differently from papillary and chromophobe. Staging adds imaging of the chest, and assessment of whether tumor extends into the renal vein or the vena cava, which changes the operation.
Kidney function is measured before treatment, because how much kidney you keep is a decision, not an accident.
Staging explained simply
Size and whether the tumor has broken out of the kidney drive the stage. Kidney cancer has a habit of growing along the renal vein toward the heart — surgeons look for this specifically, because it changes the operation considerably.
| Stage | What it means in plain words |
|---|---|
| Stage I | 7 cm or smaller, confined to the kidney. Often removed with only part of the kidney. |
| Stage II | Larger than 7 cm but still confined to the kidney. |
| Stage III | Extends into major veins or surrounding fat, or involves nearby lymph nodes. |
| Stage IV | Grown beyond the kidney's surrounding envelope, or spread to distant organs. |
Grading and biology
Clear cell kidney cancer is graded 1–4 on the WHO/ISUP scale, based on how prominent the nucleoli are and how disordered the cells look. Higher grade means faster-behaving disease and is an independent predictor of outcome alongside stage.
Sarcomatoid features, when present, mark more aggressive disease and influence treatment choice. In advanced disease, the subtype and molecular features guide which targeted or immune therapy is used.
How it’s treated
Surgery is the mainstay. Where possible, only the tumor and a rim of tissue is removed (partial nephrectomy), preserving kidney function — this matters for long-term heart and kidney health, not just tidiness. Larger or centrally placed tumors may need the whole kidney.
Active surveillance is legitimate for small masses, particularly in older patients or those with other health problems. Many small kidney tumors grow very slowly, and monitoring can be safer than operating.
Ablation — freezing or heating the tumor through the skin — treats small tumors without surgery.
Immunotherapy and targeted therapy have transformed advanced kidney cancer. Combinations of checkpoint inhibitors with targeted agents produce long responses in a meaningful proportion of patients.
Radiation was long thought useless here, and that belief is now outdated. Kidney cancer resists conventional low-dose-per-day radiation, but responds to stereotactic body radiation therapy (SBRT) — very high doses in a few sessions. SBRT is used for primary tumors in people who cannot have surgery, and is highly effective for bone and brain metastases and for controlling a few slowly progressing sites.
Where CureRays fits: SBRT is our field. If you have been told radiation does not work for kidney cancer, that was true of the old technique, not the current one.
What the guidelines say
In broad strokes: remove localized disease with kidney-sparing surgery where feasible; consider surveillance or ablation for small masses; offer adjuvant immunotherapy for selected high-risk resected disease; treat advanced disease with immunotherapy-based combinations chosen by risk group and subtype; and use SBRT for local control and for metastatic sites.
Your team will follow national guidelines such as those from the National Comprehensive Cancer Network (NCCN). The above is a plain-language overview of the general approach, not the guideline itself. NCCN publishes free NCCN Guidelines for Patients®.
Outcomes and odds of cure
Source: NCI SEER Cancer Stat Facts: Kidney and Renal Pelvis Cancer, SEER 21 (excluding IL), 2015–2021.
| When it is found | Share of cases | 5-year relative survival |
|---|---|---|
| Localized — confined to the kidney | 66% | 93.3% |
| Regional — spread to nearby lymph nodes | 16% | 76.4% |
| Distant — spread to other organs | 15% | 19.1% |
| Unstaged | 3% | 54.3% |
These are population statistics from the National Cancer Institute's SEER program. They describe large groups of people, not any one person, and lag current treatment by several years. They cannot predict what will happen to you.
The distant-stage figure deserves context: it reflects people diagnosed from 2015, and immunotherapy combinations have moved this number considerably since. Kidney cancer death rates have been falling about 1.4% a year (SEER, 2014–2023).
Side effects and how we watch for them
After surgery, the main long-term consideration is kidney function — which is why removing only part of the kidney is preferred when it is safe. Blood pressure and kidney blood tests are monitored afterwards.
Targeted therapies commonly cause high blood pressure, fatigue, hand-foot skin reaction, diarrhea and thyroid changes. Blood pressure often needs treating and is not a reason to stop the drug.
Immunotherapy can cause the immune system to attack normal organs — bowel, thyroid, liver, lungs, skin. Report new diarrhea, rash, breathlessness or unusual fatigue the day it starts.
SBRT is generally well tolerated; effects depend on the site treated.
How it is assessed: graded on a standard scale at each visit, with scheduled blood pressure, thyroid, liver and kidney monitoring.
Follow-up, remission and survivorship
Remission means no detectable cancer. Kidney cancer can recur late — occasionally many years later — so follow-up runs longer than for many cancers.
Typical follow-up combines imaging of the abdomen and chest and kidney function blood tests, most frequent in the first three years and continuing for at least five, longer for higher stages.
Survivorship centres on protecting the kidney you have: blood pressure control, avoiding unnecessary anti-inflammatory drugs, staying hydrated, and not smoking. If your cancer was young-onset or bilateral, ask about genetic counselling for your relatives.
Questions people actually ask
They found it by accident. Does that mean it is not serious?
It means it was probably found earlier than it would have been otherwise, which is good news. It still needs proper staging and a plan — but incidental discovery is the single biggest reason more kidney cancers are now caught at a curable stage.
Can I live normally with one kidney?
Most people can. One healthy kidney compensates well. That said, surgeons preserve kidney tissue when they safely can, because long-term kidney function affects heart health too.
Is watching a small tumor really safe?
For selected small masses, yes — many grow very slowly, and surveillance avoids the risks of surgery. It is an active plan with scheduled imaging, not a decision to ignore it.
I was told radiation does not work for kidney cancer.
That was true of conventional daily low-dose radiation. Kidney cancer does respond to stereotactic body radiation therapy, which delivers much higher doses in a few sessions. It is a reasonable option when surgery is not, and valuable for metastases.
Why is my blood pressure being checked so often?
Some targeted drugs raise blood pressure — it is a common, expected and treatable effect, and sometimes even a sign the drug is working. It is managed, not a reason to stop.
Informational only, not medical advice — confirm with your care team.
Go deeper on kidney cancer
Read the full plain-language guide, or ask us whether SBRT has a role for you.